Biote CORP 8-K filings

Biote Corp. announced second quarter 2026 financial results showing a 9.5% revenue decrease to $44.2 million and a net loss of $7.4 million, largely due to a voluntary product recall.

Biote Corp. announced a leadership transition with Bret Christensen stepping down as CEO, Robert Peterson appointed Interim CEO, and Marc Beer becoming Executive Chairman, while reaffirming 2026 guidance.

Biote Corp. announced the results of its 2026 annual meeting of stockholders, including the election of two Class I directors and the ratification of its independent auditor.

Biote Corp. announced first quarter 2026 financial results, reporting $44.9 million in revenue and a net income of $2.7 million, impacted by a voluntary product recall.

Biote Corp. released its investor presentation for April 2026, detailing 2025 financial results and providing a 2026 outlook, emphasizing growth in therapeutic wellness.

Biote Corp.'s subsidiary, Asteria Health, initiated a voluntary recall of specific hormone pellet lots due to potential metal particulate matter, expecting a $1.3M Q4 charge and $1.0M in 2026 costs.

Biote Corp. reported a 6.7% revenue decline to $48.0 million in Q3 2025, with net income falling to $9.2 million, while reiterating its full-year financial guidance.

Biote Corp. reported a significant increase in net income and Adjusted EBITDA for Q2 2025, driven by strong dietary supplement sales and gross margin expansion, despite a slight revenue decrease and a downward revision of full-year 2025 guidance.

Biote Corp. announced the appointment of Richard R. Barrera, founder and portfolio manager of Roystone Capital, to its Board of Directors, bringing extensive finance and investment expertise.

Biote Corp. reported the immediate resignation of Steven J. Heyer from its Board of Directors, effective June 2, 2025, with the company stating the departure was not due to any disagreements.

Biote Corp. held its 2025 annual meeting of stockholders on May 13, 2025, and elected directors and ratified the appointment of Deloitte & Touche LLP as its independent accounting firm.

Biote Corp. announces its Q1 2025 financial results, highlighting revenue growth, increased gross profit margin, and a strategic organizational restructuring to drive sustainable growth.

Biote Corp.'s Executive Chairman, Marc Beer, transitioned to a part-time role on April 1, 2025, leading to a proportionate reduction in his annual base salary.

Biote Corp. is leveraging its hormone optimization leadership to expand into the therapeutic wellness market, targeting a substantial addressable market with its technology-driven platform.

Biote Corp. reports a 6.4% increase in full-year revenue for 2024 and provides its financial outlook for fiscal year 2025.

Biote Corp. has announced the retirement of CEO Teresa Weber, effective February 1, 2025, and the appointment of Bret Christensen as her successor.

Biote Corp. announced its third quarter 2024 financial results, highlighting revenue growth, improved gross profit margins, and the launch of new clinical decision support software.

Biote Corp. announced its second quarter 2024 financial results, showing a sequential increase in procedure revenue growth but a net loss, while reaffirming its full-year financial guidance.

Biote Corp. has entered into a settlement agreement to repurchase shares from a stockholder, Marci M. Donovitz, for $60 million, resolving a litigation matter.

Biote Corp. has announced the termination of Mary Puncochar, Head of Strategic Sales & Business Analytics, effective July 2, 2024, with a separation agreement in place.

Biote Corp. has agreed to repurchase approximately 8.3 million shares and cancel 4.0 million earnout shares from a stockholder for $60 million to resolve litigation.

Biote Corp. held its 2024 annual meeting of stockholders, electing three Class II directors and ratifying the appointment of Deloitte & Touche LLP as its independent auditor.

Biote Corp. announced a 4.4% increase in revenue to $46.8 million for the first quarter of 2024, driven by a 6.6% rise in procedure revenue and improved gross profit margins.

Biote Corp. has reached a settlement with its founder, Dr. Gary S. Donovitz, involving a $76.9 million share repurchase and the resolution of outstanding litigation.

Biote Corp.'s investor presentation outlines its position as a leader in hormone optimization and its expansion into the broader therapeutic wellness market.

Biote Corp. announced its fourth quarter and full year 2023 financial results, highlighting revenue growth, increased gross profit margins, and a strategic share repurchase program.

Biote Corp. has reached a settlement to resolve litigation with its founder, Dr. Gary S. Donovitz, and will repurchase his shares for approximately $76.9 million.

Biote Corp. has authorized a $20 million share repurchase program, signaling confidence in its growth and strategic objectives.

Biote Corp. reported preliminary 2023 financial results slightly below previous guidance and announced the acquisition of Asteria Health to vertically integrate hormone product manufacturing.

Biote Corp. has appointed Robert Peterson as its new Chief Financial Officer, effective January 8, 2024, succeeding Samar Kamdar who will remain with the company through February 29, 2024 to assist with the transition.